Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) - HARRP

Study identifier:D1843R00345

ClinicalTrials.gov identifier:NCT06099067

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus

Medical condition

Type 2 Diabetes Mellitus

Phase

-

Healthy volunteers

No

Study drug

Canagliflozin, DPP4 inhibitor, Liraglutide, Saxagliptin, 2nd generation Sulfonylurea

Sex

All

Actual Enrollment

239990

Study type

Observational

Age

N/A

Date

Study Start Date: 15 May 2020
Primary Completion Date: 31 Aug 2023
Study Completion Date: 31 Aug 2023

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria